FDA To Review Takeda’s sNDA For Velcade
Containing long-term survival data for Velcade for injection
FDA has accepted to review Takeda’s supplemental new drug application (sNDA) based on long-term overall survival (OS) data from the VISTA 1 trial. The study examined the use of Velcade-based therapy in patients with previously untreated multiple myeloma (MM).
Vista trail, conducted by Millennium Pharmaceuticals (Millennium) was a multicenter, international phase III clinical trial. It compared Velcade in combination with melphalan and prednisone (VcMP) versus melphalan and prednisone (MP) alone, in patients with previously untreated MM who were not eligible for stem cell transplantation.
Reportedly, in VISTA, the VcMP arm demonstrated a significant improvement in all efficacy endpoints, including time-to-tumor progression, complete response, overall response, progression-free survival and OS compared to the MP arm.
Nancy Simonian, CMO, Millennium, said: “This is the largest phase III registration study to report long-term overall survival in previously untreated multiple myeloma patients.This submission of data from the pre-planned long-term survival assessment represents an important milestone in the development of Velcade.”
Related Insight
Suppliers Directory
AqVida Oncology - High Barrier to Entry Oncology Generics and Biosimilars
The main focus of AqVida Oncology lies with the development and manufacturing of innovative products, particularly high barrier to entry oncology generics and biosimilars.
Suppliers
Burkert Fluid Control Systems - Fluid and Gas Control Systems
From the control room to the downstream processing area and with an eye on utilities services the scope of systems and components from Bürkert Fluid Control Systems and our alliance partner BBS Systems makes one of the most comprehensive partnerships in the pharmaceutical and biotechnology segments available to you today.
Suppliers
BARC - Global Central Laboratory
With 25 years experience supporting clinical trials, BARC is an independent global central laboratory that supports the life sciences industry in the development and approval of new therapeutic agents by managing the laboratory component of phase I-IV clinical trials.
Contract Research & Services > Contract Research > Suppliers
Medpace - Therapeutically Focused Clinical Development
Medpace is a leading global full-service clinical research organization providing Phase I-IV core development services for drug, biologic, and device programs. With medical and regulatory expertise in multiple therapeutic specialties, Medpace has assembled the industry’s most experienced and therapeutically focused teams to execute at every level of the company’s operations, providing complete and seamless drug development services.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
Dokumeds Company Brochure
Published by DOKUMEDS
White Papers
Offshore Outsourcing in Regulatory Affairs and Pharmacovigilance
Published by Kinapse
White Papers
Reducing Risk with the Right CRO Partner
Published by INC Research
White Papers
Pharmacological Diversity Set and 3D Diversity Set
Published by Enamine
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.